Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythromycin in Critically Septic Patients
NCT04665089Completed
- Sponsor
- University of Tunis
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in sepsis and septic shock comparing Erythromycin Arm with Placebo Arm (2 arms). Primary endpoint: Change of TNF alpha / IL-10 ratio at Day 6. Started Jan 2022; status: completed.
02
Drugs
erythromycin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT04665089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665089.